-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 18, Tiansli announced that Jiangsu Diyi, a wholly-owned subsidiary, had received a "Notice of Approval of Drug Supplemental Application" issued by NMPA on the specification of 25 mg of chlorine and nitrogen tablets, and that the drug had been evaluated through generic consistency.
chlorine and nitrogen tablets are used to treat refractic schizophrenia, are essential national medicines, and are included in the National Health Insurance Directory (Category A).
Jiangsu Diyi submitted the application for the drug's consistency evaluation to the State Drug Administration on January 20, 2020 and was accepted on February 7, 2020.
date of this announcement, Jiangsu Diyi has invested approximately RMB 827.8 million in research and development for the drug's consistency evaluation.
as of this announcement date, the main manufacturers of the drug in China are Jiangsu Enhua Pharmaceuticals, Shanghai Pharmaceutical Xinyi Pharmaceuticals, Hunan Dongting Pharmaceuticals, Ningbo Big Red Eagle Pharmaceuticals and so on.
according to the Minne database, the annual sales of chlorine-nitrogen tablets in urban public hospitals in 2019 were $99.38 million.
